A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
NCT01740271
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
Epirubicin
Sponsor
AHS Cancer Control Alberta